Overexpression of PGC1α (PPARGC1A) in certain human melanomas has been shown to exhibit enhanced mitochondrial metabolism and increased capacity for ROS detoxification, promoting survival under oxidative stress, while PGC1α‐negative melanoma cells demonstrate increased glycolytic capacities and exhibit heightened sensitivity to ROS‐inducing therapies [11]. This evidence concerns the gene PPARGC1A and melanoma.